IL2 and cancer: In contrast, there was a highly significant reduction in the proportion of cancer patients mounting T‐cell responses following the first dose (p < 0·0001, Table 2), whereby only 27 of 56 (48·2%) and 32 of 55 (58·2%) cancer patients mounted an IFN‐γ (Figure 3C) or IL‐2 (Figure 3D) response, respectively.